pancreatic cancer
Conditions
Interventions
Experimental group:Neoadjuvant chemotherapy + surgery + adjuvant chemotherapy
Control group:Surgery + adjuvant chemotherapy
Sponsors
Huadong Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. If the following criteria are met at the same time, the subject will enter the research cohort Voluntarily participate and sign the informed consent; 2. Aged 18 to 75 years, gender is not limited; 3. ECOG score = 3 months; 8. No serious hematopoietic dysfunction, abnormal heart, lung, liver, kidney function and immune deficiency, laboratory test results meet the following standards: blood routine indicators: white blood cells (WBC) >= 3 x 10^9/L; neutrophils Absolute cell count (ANC) >= 1.5 x 10^9/L; Platelet (PLT) >= 100 x 10^9/L; Hemoglobin (Hgb) >= 9g/dL; Blood biochemical indexes: AST (SGOT), ALT (SGPT) <= 2.5 x Upper limit of normal (ULN); total bilirubin (TBIL) <= ULN; serum creatinine (CRE) <= 1.5 x ULN; coagulation function: prothrombin time (PT), international normalized ratio (INR)<= 1.5x ULN; 9. Women with potential fertility are willing to take medically approved contraceptive measures in the trial; Able to comply with study visit plans and other protocol requirements.
Exclusion criteria
Exclusion criteria: 1. Patients with central nervous system disease, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other uncontrollable serious diseases; 2. Uncontrolled infection, hemorrhage, pancreatic leakage, bile leakage, or other postoperative complications during the baseline examination; acute and chronic metabolic acidosis (including ketoacidosis, lactic acidosis) cannot be corrected; 3. Those with a history of other malignant tumors; 4. Have a history of allergy to the study drug or drugs of similar structure; 5. Pregnant and lactating women; 6. Patients have received any form of anti-tumor therapy before enrollment, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy; 7. Other reasons that the investigator considers unsuitable to participate in clinical research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Radical resection rate;Safety parameters; | — |
Countries
China
Contacts
Public ContactJiang Chongyi
Huadong Hospital, Fudan University
Outcome results
None listed